Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells. The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and Hemophilia A with Factor VIII alloantibodies. Its product candidate pipeline also includes MuSK-CAART, a preclinical stage product to treat a subset of patients with myasthenia gravis; FVIII-CAART, a discovery stage product to treat a subset of patients with Hemophilia A; and DSG3/1-CAART, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. Cabaletta Bio, Inc. has a collaboration with the University of Pennsylvania; and research agreement with The Regents of the University of California. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
IPO Year: 2019
Exchange: NASDAQ
Website: cabalettabio.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/10/2025 | $14.00 | Buy | Jefferies |
| 12/20/2024 | $15.00 → $6.00 | Outperform → In-line | Evercore ISI |
| 12/19/2024 | $12.00 → $6.00 | Overweight → Equal Weight | Wells Fargo |
| 10/10/2024 | $10.00 | Buy | UBS |
| 2/5/2024 | $36.00 | Buy | Jefferies |
| 11/29/2023 | $38.00 | Outperform | William Blair |
| 10/24/2023 | $40.00 | Overweight | Cantor Fitzgerald |
| 10/19/2023 | $31.00 | Buy | Stifel |
| 9/5/2023 | $22.00 | Buy | Citigroup |
| 7/18/2023 | $34.00 | Buy | Guggenheim |
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - Cabaletta Bio, Inc. (0001759138) (Issuer)
4 - Cabaletta Bio, Inc. (0001759138) (Issuer)
4 - Cabaletta Bio, Inc. (0001759138) (Issuer)
4 - Cabaletta Bio, Inc. (0001759138) (Issuer)
4 - Cabaletta Bio, Inc. (0001759138) (Issuer)
4 - Cabaletta Bio, Inc. (0001759138) (Issuer)
4 - Cabaletta Bio, Inc. (0001759138) (Issuer)
4 - Cabaletta Bio, Inc. (0001759138) (Issuer)
Fastest customizable press release news feed in the world
83% of dermatomyositis patients in the Phase 1/2 RESET-Myositis study would have met the registrational primary endpoint; all these patients maintained their response off immunomodulators through latest follow-up, as long as 1.5 years First juvenile dermatomyositis (JDM) patient demonstrated moderate TIS response off immunomodulators and maintained their response through latest follow-up at 32 weeks; JDM expected to be included in 2H27 myositis BLA submission, facilitating the potential for a priority review voucher Systemic sclerosis (SSc) announced as second pivotal indication based on convincing Phase 1/2 data after a single dose of rese-cel upon discontinuation of immunomodulators; s
Preconditioning-free (PC-free) 6-to-9-month clinical data with a single infusion of the lowest dose of rese-cel in the RESET-PV® study presented today at ASGCT 2026 Annual Meeting along with initial rese-cel translational data using Cellares' industrialized, automated manufacturing PC-free rese-cel initial data from the lowest dose RESET-SLE™ cohort expected in 1H26 Pivotal RESET-Myositis® cohort with outpatient dosing option progressing to support first planned BLA submission for rese-cel next year Second pivotal indication for advancement to be announced after presentation of complete Phase 1/2 lupus and scleroderma data during June 2026 EULAR Congress PHILADELPHIA, May 14, 2026 (GLO
A single infusion of the lowest dose of rese-cel administered without preconditioning, after discontinuation of all immunomodulators, demonstrated compelling drug-free responses for 6 months in 2 of 4 refractory patients; next dose cohort actively enrolling Translational data from the first two patients dosed with rese-cel manufactured on the automated Cell Shuttle™ platform showed pharmacokinetic and pharmacodynamic data consistent with other patients dosed in the RESET™ clinical program ASGCT 2026 presentations reinforce Cabaletta's focus on optimizing the patient and physician experience through simplified treatment regimens and scalable reliable manufacturing PHILADELPHIA, May 14,
PHILADELPHIA, May 04, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. ("Cabaletta" or the "Company") (NASDAQ:CABA), a clinical-stage biotechnology company focused on developing and launching curative targeted cell therapies designed specifically for patients with autoimmune diseases, announced today the pricing of an underwritten offering of 51,725,000 shares of common stock. The aggregate gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $150 million. The offering is expected to close on or about May 5, 2026, subject to the satisfaction of customary closing conditions. The financing included parti
Agreement positions Cellares as a long-term commercial manufacturing partner for rese-cel, enabling thousands of batches per year at a cost per batch that is among the lowest in the industry Cellares' Cell Shuttle™ and Cell Q™ platforms can support future commercial production of rese-cel for thousands of patients per year, pending FDA approval, across a global network of IDMO Smart Factories Cellares, the first Integrated Development and Manufacturing Organization (IDMO), today announced it has entered into a 10-year commercial supply agreement with Cabaletta Bio Inc. (NASDAQ:CABA) for the automated manufacture of rese-cel (resecabtagene autoleucel), Cabaletta's investigational CAR
Agreement facilitates flexible, scalable automated industrialized production of rese-cel for many thousands of patients per year at a cost per batch that is among the lowest in the industry Initial translational data from the first two patients dosed with rese-cel manufactured by Cellares will be presented at the ASGCT conference in May PHILADELPHIA and SOUTH SAN FRANCISCO, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (NASDAQ:CABA), a late-stage clinical biotechnology company focused on developing and launching curative targeted cell therapies designed specifically for patients with autoimmune diseases, and Cellares, the first Integrated Development and Manufacturing O
PHILADELPHIA, April 27, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (NASDAQ:CABA), a late-stage clinical biotechnology company focused on developing and launching targeted cell therapies designed specifically for patients with autoimmune diseases, today announced multiple upcoming presentations including manufacturing, translational and clinical data on rese-cel (resecabtagene autoleucel) at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting, being held from May 11-15, 2026, in Boston, MA. The presentations will feature clinical and translational data from the lowest dose cohort of rese-cel without preconditioning in RESET-PV® (pemphigus vulgaris), and initial transl
First two GMP doses of rese-cel manufactured on the Cell Shuttle™ met all release specifications, were delivered on time, and have been infused into patients within Cabaletta Bio's RESET™ clinical trial program. Cellares, the first Integrated Development and Manufacturing Organization (IDMO), today announced that Cabaletta Bio Inc.'s ("Cabaletta Bio" or "Cabaletta") (NASDAQ:CABA) investigational CAR T cell therapy rese-cel (resecabtagene autoleucel) has been infused into the first two patients using drug product manufactured on Cellares' Cell Shuttle™ automated manufacturing platform. The administration of an autologous cell therapy, which met all release criteria and was manufactured on
Rese-cel myositis BLA submission on track for 2027 based on a 17-patient, single arm registrational cohort design, including an outpatient dosing option No-preconditioning program enrolling in lupus and PV; anticipating initial RESET-SLE™ data in 1H26 and durability data from the RESET-SLE and RESET-PV® trials throughout 2026 Automated manufacturing of rese-cel with Cellares' Cell Shuttle™ underway in the RESET™ clinical program, offering the potential to produce rese-cel for thousands of patients per year with minimal capital investment Pivotal trial designs announced for SLE and LN single arm cohorts, each with ~25 patients; on track to announce SSc design in 1H26; FDA registrational d
PHILADELPHIA, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (NASDAQ:CABA), a late-stage clinical biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that the Company will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026, at 11:10 a.m. ET in Boston, MA. A live webcast of the presentation will be available on the News and Events section of the Company's website at www.cabalettabio.com. Replays will be available on the website for 30 days. About Cabaletta BioCabaletta Bio (NASDAQ:CABA) is a late-stage
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - Cabaletta Bio, Inc. (0001759138) (Issuer)
4 - Cabaletta Bio, Inc. (0001759138) (Issuer)
4 - Cabaletta Bio, Inc. (0001759138) (Issuer)
4 - Cabaletta Bio, Inc. (0001759138) (Issuer)
4 - Cabaletta Bio, Inc. (0001759138) (Issuer)
4 - Cabaletta Bio, Inc. (0001759138) (Issuer)
4 - Cabaletta Bio, Inc. (0001759138) (Issuer)
4 - Cabaletta Bio, Inc. (0001759138) (Issuer)
4 - Cabaletta Bio, Inc. (0001759138) (Issuer)
4 - Cabaletta Bio, Inc. (0001759138) (Issuer)
8-K - Cabaletta Bio, Inc. (0001759138) (Filer)
DEFA14A - Cabaletta Bio, Inc. (0001759138) (Filer)
SCHEDULE 13G/A - Cabaletta Bio, Inc. (0001759138) (Subject)
10-Q - Cabaletta Bio, Inc. (0001759138) (Filer)
8-K - Cabaletta Bio, Inc. (0001759138) (Filer)
8-K - Cabaletta Bio, Inc. (0001759138) (Filer)
8-K - Cabaletta Bio, Inc. (0001759138) (Filer)
424B5 - Cabaletta Bio, Inc. (0001759138) (Filer)
8-K - Cabaletta Bio, Inc. (0001759138) (Filer)
DEFA14A - Cabaletta Bio, Inc. (0001759138) (Filer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Live Leadership Updates
Jefferies resumed coverage of Cabaletta Bio with a rating of Buy and set a new price target of $14.00
Evercore ISI downgraded Cabaletta Bio from Outperform to In-line and set a new price target of $6.00 from $15.00 previously
Wells Fargo downgraded Cabaletta Bio from Overweight to Equal Weight and set a new price target of $6.00 from $12.00 previously
UBS initiated coverage of Cabaletta Bio with a rating of Buy and set a new price target of $10.00
Jefferies initiated coverage of Cabaletta Bio with a rating of Buy and set a new price target of $36.00
William Blair initiated coverage of Cabaletta Bio with a rating of Outperform and set a new price target of $38.00
Cantor Fitzgerald initiated coverage of Cabaletta Bio with a rating of Overweight and set a new price target of $40.00
Stifel initiated coverage of Cabaletta Bio with a rating of Buy and set a new price target of $31.00
Citigroup initiated coverage of Cabaletta Bio with a rating of Buy and set a new price target of $22.00
Guggenheim initiated coverage of Cabaletta Bio with a rating of Buy and set a new price target of $34.00
Rese-cel data presented at multiple medical meetings demonstrated potentially transformative, drug-free clinical responses with a favorable safety profile for autoimmune patients supporting outpatient use All myositis patients in the Phase 1/2 DM/ASyS cohort with sufficient follow-up who would have met key criteria for the registrational cohort met the registrational, 16-week primary endpoint Planned BLA submission for rese-cel in 2027 based on 14-patient, single-arm DM/ASyS registrational cohort initiating enrollment this quarter within the RESET-Myositis™ trial FDA alignment on additional registrational cohort designs for RESET-SSc™ and RESET-SLE™ anticipated by year-end 2025 PHILADEL
– Gavel brings highly relevant CAR T experience from Legend Biotech where he led the launch and commercialization of CARVYKTI® from 2018 until 2025 – PHILADELPHIA, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (NASDAQ:CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced the appointment of Steve Gavel as Chief Commercial Officer, effective immediately. In his role, Mr. Gavel will join the leadership team and will lead all aspects of global commercial strategy and execution for rese-cel (resecabtagene autoleucel, formerly CABA-201), for
– Ms. Tomasello created and led global commercial and medical affairs functions at Kite Pharma from pre-launch through its acquisition by Gilead Sciences – PHILADELPHIA, July 24, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (NASDAQ:CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced the appointment of Shawn Tomasello to its Board of Directors. Ms. Tomasello has over 35 years of experience in the life sciences industry, including specific expertise in CD19-CAR T therapy, where she most recently served as the Chief Commercial Officer of Kite Pharma, Inc. between 20
Dr. Brun also appointed as Chairperson of Jasper Research and Development Committee and to Compensation Committee Board member Vishal Kapoor appointed to Jasper Audit and Compensation Committees REDWOOD CITY, Calif., June 20, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a biotechnology company focused on the development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria (CSU), lower to intermediate risk myelodysplastic syndromes (LR-MDS) as well as novel stem cell transplant conditioning regimes, today announced the appointment of Scott Brun, M.D., to Jasper's Board of Directors. Dr. Bru
PHILADELPHIA, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (NASDAQ:CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that Michael Gerard has been appointed general counsel. "We are very pleased to welcome Mike to the executive team. His experience with a wide range of strategic legal and corporate matters within the life sciences industry will complement the management team as we advance clinical development for DSG3-CAART in our DesCAARTes™ trial, and further develop follow-on candidates from our deep pipeline of precision therapies for pati
Dr. Brun's early and late-stage clinical development expertise in autoimmune, neurologic, and renal disease areas aligns well with Cabaletta's rapidly emerging pipeline PHILADELPHIA, June 28, 2021 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (NASDAQ:CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced the appointment of veteran biopharmaceutical leader, Scott Brun, M.D., to its Board of Directors. Dr. Brun has over 20 years of wide-ranging drug development and business development experience, including his time as Vice President and Head of Pharmaceutical Deve
This live feed shows all institutional transactions in real time.
SC 13G/A - Cabaletta Bio, Inc. (0001759138) (Subject)
SC 13G/A - Cabaletta Bio, Inc. (0001759138) (Subject)
SC 13G/A - Cabaletta Bio, Inc. (0001759138) (Subject)
SC 13G/A - Cabaletta Bio, Inc. (0001759138) (Subject)
SC 13G/A - Cabaletta Bio, Inc. (0001759138) (Subject)
SC 13G - Cabaletta Bio, Inc. (0001759138) (Subject)
SC 13G/A - Cabaletta Bio, Inc. (0001759138) (Subject)
SC 13G/A - Cabaletta Bio, Inc. (0001759138) (Subject)
SC 13G/A - Cabaletta Bio, Inc. (0001759138) (Subject)
SC 13G/A - Cabaletta Bio, Inc. (0001759138) (Subject)
Live finance-specific insights
– CABA-201 safety profile suggests favorable risk-benefit with no CRS or ICANS in the majority of patients; low-grade CRS in three of eight patients and one previously reported ICANS event – – Compelling clinical responses observed in lupus and myositis patients with up to six months of follow-up; first SSc patient demonstrated an emerging, drug-free clinical response – – All eight patients with active, refractory autoimmune disease discontinued all immunosuppressants prior to CABA-201 infusion and through the follow-up period – – Consistent and complete B cell depletion observed in all patients within the first month after CABA-201 infusion; evidence of transitional naïve B cell repopula
– Clinical data from the RESET-Myositis™ and RESET-SLE™ trials, along with initial clinical data from the RESET-SSc™ trial, to be presented this weekend in oral and poster presentations at ACR Convergence 2024 – – 16 patients enrolled with 10 patients dosed as of November 12 across the RESET™ clinical development program; 40 U.S. clinical sites actively recruiting patients – – Data permitting, anticipate meeting with the FDA in 2025 regarding potential registrational program designs for CABA-201 – – Clinical development expanding efficiently into Europe with EMA CTA authorization for CABA-201 received in lupus; Gerwin Winter appointed as Senior VP and Head of International – – Cash, cash
– No CRS, ICANS, infections or serious adverse events observed in either of the first two patients through data cut-off of May 28, 2024 – – CABA-201 exhibited anticipated profile of CAR T cell expansion and contraction with complete B cell depletion observed in both patients by day 15 post-infusion – – Improvements in both patients' specific disease measures, consistent with academic experience of a similar 4-1BB CD19-CAR T, suggest emerging clinical benefit with CABA-201 while discontinuing all disease-specific therapies other than a planned steroid taper in one patient – – Immature, naïve B cell repopulation in first IMNM patient observed at week 8 consistent with a potential immu
PHILADELPHIA, March 16, 2021 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced financial results for the fourth quarter and full year ended December 31, 2020. “At the end of 2020, we achieved an important milestone when we dosed the first patient without any dose limiting toxicities in our Phase 1 clinical trial for DSG3-CAART, our lead product candidate being developed for the treatment of patients with mucosal pemphigus vulgaris. This is the first time a highly targeted, antigen specific cell therapy h